Truist on Insmed (INSM): 'We See a Favorable Risk/Reward Profile'

Truist Securities analyst Nicole Germino reiterated a Buy rating and $108.00 price target on Insmed (NASDAQ: INSM).

The analyst commented: "Heading into PAH data, we see a favorable risk/reward profile; Heading into TPIP data for pulmonary arterial hypertension (PAH) reading out ahead of the brenso commercial launch pending approval Aug 12, 2025, we see potential ~60% upside/~35% downside from current levels based on assumptions using our model (see scenario analysis table below). In our view, we remain confident into TPIP PAH data given positive data we've seen so far and assume an encouraging brensocatib commercial launch. From recent investor discussions, we're getting questions around 1) TPIP data for PAH, 2) chronic rhinosinusitis sans nasal polyps (CRSsNP) opportunity & bronchiectasis launch ramp. Reiterate Buy rating and $108 PT."

For an analyst ratings summary and ratings history on Insmed click here. For more ratings news on Insmed click here.

Shares of Insmed closed at $73.07 yesterday.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• Investec Double Upgrades Alkem Laboratories Ltd (ALKEM:IN) to Buy